|Bid||74.59 x 90000|
|Ask||74.68 x 90000|
|Day's Range||74.37 - 74.91|
|52 Week Range||51.69 - 75.21|
|Beta (3Y Monthly)||0.37|
|PE Ratio (TTM)||50.45|
|Forward Dividend & Yield||1.13 (1.52%)|
|1y Target Est||N/A|
Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday. The study, which was presented at the American Diabetes Association meeting in San Francisco, assessed the medical records of 363 type 2 diabetics in France, Germany and Austria between three and six months. Dr. Helene Hanaire of the University Hospital Center of Toulouse, France, one of the study authors, said having ready access to their blood glucose readings helped diabetics become more engaged with controlling their glucose levels.
Prepare for more churn around these levels, said Mark Tepper , president of Strategic Wealth Partners. "We're really trying to target good companies that are big players in investible themes, and health care as a sector has struggled this year but it's been resilient over the past month. As the S&P 500 has tumbled 4% this month, the XLV health care sector ETF has held slightly positive.
The Minnesota Democrat disclosed in a regulatory filing that a joint account with her husband Archie Smith has sold $250,001 to $500,000 of shares in the health-care giant.
The largest Insider Buys this week were for Abbott Laboratories, Morgan Stanley, Crown Castle International Corp and Pinterest Inc.
These two marijuana stocks reported very different results last quarter. Plus, how Abbott's challenging Dexcom in diabetes, and what's next for Bristol-Myers following its Celgene acquisition.
Benzinga has examined prospects for many investor favorite stocks over the past week. Bullish calls included a leading airline and a pharmaceutical giant. And bearish calls included cruise line operators ...
Medical device companies like Abbott, Medtronic and Tandem Diabetes are jockeying for a piece of the diabetes treatment market, which could be worth north of $2 trillion by 2030.
Health care company Abbott Laboratories (NYSE: ABT ) has had a strong start to the year with forecast-beating first-quarter results and in-line full-year guidance. The Analyst Raymond James analyst Jayson ...
Abbott Laboratories' earnings and sales topped first-quarter estimates, but the medical products giant retained its prior full-year outlook and Abbott stock slipped at the close Wednesday.
Check out the companies making headlines midday Wednesday:Qualcomm QCOM — Qualcomm surged 12.3%, adding to Tuesday's gains after news broke that the chipmaker reached a settlement with Apple over their royalty dispute , dropping all legal action between the two companies worldwide.
Abbott Laboratories Inc reported higher-than-expected quarterly profit and sales on surging demand for its glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge. Healthcare stocks have been under pressure due to concerns over new regulations, more so after U.S. Senator Bernie Sanders unveiled the latest version of his "Medicare-for-All" plan that would eliminate private insurance and shift all Americans to a public healthcare plan. Abbott shares were down 4 percent, with most other major U.S. device makers also down between 1 percent and 2 percent.
were down 2.8% in trading Wednesday despite the drug company and medical device maker reporting first-quarter earnings that topped its own forecast. Analysts polled by FactSet were expecting the company to report earnings of 61 cents per share on revenue of $7.48 billion. "We're right on track with our expectations to start the year," said Abbott's Chairman and CEO Miles D. White.
(Reuters) - Abbott Laboratories Inc reported higher-than-expected first-quarter profit and sales on Wednesday on surging sales of its Freestyle Libre glucose monitoring device and as more of its heart ...
Abbott reported adjusted earnings of 63 cents per share on revenue of $7.5 billion, a 2% year-over-year increase. Analysts polled by FactSet were expecting the company to report earnings of 61 cents per share on revenue of $7.48 billion. "We're right on track with our expectations to start the year," said Abbott's Chairman and CEO Miles D. White.
The Abbott Park, Illinois-based company said it had profit of 38 cents per share. Earnings, adjusted for one-time gains and costs, came to 63 cents per share. The results beat Wall Street expectations. ...
Abbott Laboratories Inc reported first-quarter sales ahead of Wall Street expectations on Wednesday, on double digit growth of its Freestyle Libre glucose monitoring device and as more of its heart valves ...
The "Halftime Report" traders answer viewer questions on Abbott Labs, Pinterest, Chevron, and Intel.